The European Commission approved Pfizer's respiratory syncytial virus vaccine for the prevention of lower respiratory tract ...

Older adults and people with certain medical conditions are more likely to receive the respiratory syncytial virus (RSV) ...

The two companies say their shots show high efficacy against both the A and B strains of RSV, which remains one of the few major infectious diseases without a vaccine available. The two vaccines ...

The bivalent respiratory syncytial virus prefusion F vaccine is highly effective and well tolerated against RSV-associated ...

Pfizer has won European Commission expanded approval of its Abrysvo vaccine for respiratory syncytial virus, or RSV, for use in all adults. The New York drugmaker on Tuesday said the extended ...

England’s RSV vaccination programme has achieved a 30% reduction in RSV-related hospital admissions among older adults.

Abrysvo, which is now the first maternal RSV vaccine to be prequalified by the organisation, aims to prevent RSV-associated lower respiratory tract disease in infants during the first six months ...

Moderna’s respiratory syncytial virus (RSV) vaccine mRESVIA has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) to protect adults aged 60 years and older against lower ...

CAMBRIDGE, MA / ACCESS Newswire / March 31, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Australian Therapeutic Goods Administration (TGA) has granted approval for mRESVIA® (mRNA ...